Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Net Income	-11.22	-12.7	-9.93	-13.77	-13.13	-10.09
Depreciation & Amortization	0.04	0.04	0.05	0.04	0.06	0.09
Stock-Based Compensation	3.9	4.8	4.74	6.75	8.06	4.14
Other Adjustments	-	-	-	-	-0.01	0.15
Change in Receivables	-	0.1	-0.22	-0.03	-	0.06
Changes in Accounts Payable	-0.03	0.32	-0.06	0.13	-0.1	-0.35
Changes in Accrued Expenses	0.07	0.18	0.04	0.63	0.19	0.01
Changes in Other Operating Activities	0.07	-0.07	-0.82	-0.25	-0.02	-0.18
Operating Cash Flow	-6.85	-7.34	-6.21	-6.49	-4.94	-6.18
Capital Expenditures	-	-	-	-	-	-0.02
Sale of Property, Plant & Equipment	-	-	-	-	0.04	-
Purchases of Investments	-53.16	-63.77	-44.41	-22.49	-16.5	-5.01
Proceeds from Sale of Investments	58.24	68.05	38.81	11.76	12.54	4.72
Investing Cash Flow	5.08	4.28	-5.6	-10.73	-3.92	-0.31
Issuance of Common Stock	1.9	3.42	0.37	0.45	31.57	9.41
Repurchase of Common Stock	-	-0.01	-	-	-	-
Net Common Stock Issued (Repurchased)	1.9	3.42	0.37	0.45	31.57	9.41
Financing Cash Flow	2.04	3.42	0.37	0.45	31.57	9.41
Net Cash Flow	0.27	0.36	-11.45	-16.77	22.71	2.93
Beginning Cash & Cash Equivalents	1.23	0.92	12.36	29.13	6.42	3.49
Ending Cash & Cash Equivalents	1.5	1.27	0.92	12.36	29.13	6.42
Free Cash Flow	-6.85	-7.34	-6.21	-6.49	-4.94	-6.19
FCF Margin	-	-	-2956.67%	-	-964.45%	-
Free Cash Flow Per Share	-0.21	-0.23	-0.20	-0.21	-0.17	-0.28
Levered Free Cash Flow	-10.96	-12.09	-10.6	-13.04	-12.82	-10.47
Unlevered Free Cash Flow	-11.83	-13.37	-11.8	-13.32	-13	-10.43

Updated Sep 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q